论文部分内容阅读
BACKGROUND: Many international studies have shown that plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism does not increase the risk for cerebral infarction. OBJECTIVE: Using PCR methodology and agarose electrophoresis to detect PAI-1 4G/5G promoter polymorphism in patients with recurrent cerebral infarction in the North Jiangsu Province of China, and to compare results with healthy subjects and patients with first-occurrence cerebral infarction in the same region. DESIGN, TIME AND SETTING: Non-randomized, concurrent, control trial. A total of 122 cerebral infarction patients were admitted to Xuzhou Medical College Hospital’s Department of Neurology and Xuzhou Central Hospital’s Department of Neurology between July 2003 and August 2006. PARTICIPANTS: The patients consisted of 63 males and 59 females, aged (62 ± 10) years. They were divided into first-occurrence (n = 58) and recurrence (n = 64) groups. In addition, 50 healthy subjects that underwent physical examination in the outpatient department, including 26 males and 24 females, aged (60 ±12) years, were selected as controls. METHODS AND MAIN OUTCOME MEASURES: PAI-1 4G/5G promoter polymorphism was detected and analyzed using PCR methodology and agarose electrophoresis. RESULTS: Significant differences were determined in terms of genotypic frequency and allele frequency of PAI-1 4G/5G promoter polymorphism, in patients with first-occurrence or recurrent cerebral infarction, when compared with healthy subjects (P < 0.05). There was, however, no significant difference between the first-occurrence and recurrence groups (P > 0.05). CONCLUSION: PAI-1 4G/5G promoter polymorphism is genetic risk factor for cerebral infarction in China. However, it may be associated with recurrence of cerebral infarction in patients from the North Jiangsu Province of China.
BACKGROUND: Many international studies have shown that plasminogen activator inhibitor-1 (PAI-1) 4G / 5G promoter polymorphism does not increase the risk for cerebral infarction. OBJECTIVE: Using PCR methodology and agarose electrophoresis to detect PAI-1 4G / 5G promoter polymorphism in patients with recurrent cerebral infarction in the North Jiangsu Province of China, and to compare results with healthy subjects and patients with first-onset cerebral infarction in the same region. DESIGN, TIME AND SETTING: Non-randomized, concurrent, control trial. A total of 122 cerebral infarction patients were admitted to Xuzhou Medical College Hospital’s Department of Neurology and Xuzhou Central Hospital’s Department of Neurology between July 2003 and August 2006. PARTICIPANTS: The patients consisted of 63 males and 59 females, aged (62 ± 10) years. They were divided into first-occurrence (n = 58) and recurrence (n = 64) groups. In addition, 50 healthy subjects that underwent physical examin METHODS AND MAIN OUTCOME MEASURES: PAI-1 4G / 5G promoter polymorphism was detected and analyzed using PCR methodology and agarose electrophoresis . RESULTS: Significant differences were determined in terms of genotypic frequency and allele frequency of PAI-1 4G / 5G promoter polymorphism, in patients with first-occurrence or recurrent cerebral infarction, when compared with healthy subjects (P <0.05). There was, However, it may be associated with recurrence of cerebral infarction. However, no significant difference between the first-occurrence and recurrence groups (P> 0.05). CONCLUSION: PAI-1 4G / 5G promoter polymorphism is genetic risk factor for cerebral infarction in China. in patients from the North Jiangsu Province of China.